D. E. Shaw & Co., Inc. Taysha Gene Therapies, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $125 Billion
- Q2 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 401,509 shares of TSHA stock, worth $2.09 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
401,509Holding current value
$2.09 Million% of portfolio
0.0%Shares
6 transactions
Others Institutions Holding TSHA
# of Institutions
155Shares Held
244MCall Options Held
107KPut Options Held
17K-
Rtw Investments, LP New York, NY25MShares$130 Million0.89% of portfolio
-
Ra Capital Management, L.P. Boston, MA23.6MShares$122 Million1.19% of portfolio
-
Avoro Capital Advisors LLC New York, NY21.7MShares$113 Million0.91% of portfolio
-
Morgan Stanley New York, NY16.9MShares$87.7 Million0.0% of portfolio
-
Octagon Capital Advisors LP New York, NY12.6MShares$65.5 Million11.04% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $251M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...